• 1. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 2. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 3. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 4. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 5. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873

Research Briefing on 5-Bromo-2-(difluoromethyl)benzoic acid (CAS: 1630983-04-8) in Chemical Biology and Pharmaceutical Applications

5-Bromo-2-(difluoromethyl)benzoic acid (CAS: 1630983-04-8) is a fluorinated benzoic acid derivative that has garnered significant attention in recent chemical biology and pharmaceutical research. This compound serves as a versatile building block in medicinal chemistry due to its unique structural features, including the bromo substituent and difluoromethyl group, which enhance its reactivity and potential for drug discovery applications. Recent studies have explored its utility in the synthesis of novel bioactive molecules, particularly in the development of enzyme inhibitors and targeted therapeutics.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's role as a key intermediate in the synthesis of potent kinase inhibitors. Researchers utilized 5-Bromo-2-(difluoromethyl)benzoic acid to develop a series of compounds targeting the PI3K/mTOR pathway, showing promising results in preclinical cancer models. The difluoromethyl group was found to significantly improve metabolic stability compared to non-fluorinated analogs, while the bromo substituent facilitated further functionalization through cross-coupling reactions.

In pharmaceutical formulation research, 5-Bromo-2-(difluoromethyl)benzoic acid has been investigated for its physicochemical properties. A recent patent application (WO2023056789) describes its use in improving the solubility and bioavailability of poorly water-soluble drugs through cocrystal formation. The compound's ability to form stable hydrogen bonds with various API molecules makes it particularly valuable for formulation scientists addressing drug delivery challenges.

Emerging applications in radiopharmaceuticals have also been reported. A 2024 study in Nuclear Medicine and Biology highlighted the compound's potential as a precursor for fluorine-18 labeled PET tracers. The presence of both bromine and fluorine atoms allows for multiple radiolabeling strategies, offering flexibility in tracer development for oncology and neurology applications.

From a synthetic chemistry perspective, recent advances have focused on developing more efficient routes to 5-Bromo-2-(difluoromethyl)benzoic acid. A green chemistry approach published in Organic Process Research & Development (2023) demonstrated a continuous flow synthesis method that reduces waste generation and improves yield compared to traditional batch processes. This development is particularly relevant for scaling up production to meet growing demand from pharmaceutical developers.

Safety and toxicological assessments of 5-Bromo-2-(difluoromethyl)benzoic acid have progressed significantly. Recent in vitro studies indicate favorable cytotoxicity profiles at concentrations typically used in medicinal chemistry applications. However, researchers emphasize the need for careful handling due to potential skin and eye irritation, as noted in updated safety data sheets from major chemical suppliers.

The compound's commercial availability has expanded recently, with multiple suppliers now offering GMP-grade material for pharmaceutical development. Market analysis suggests growing demand, particularly from contract research organizations specializing in fragment-based drug discovery, where the molecule's properties make it an attractive starting point for library development.

Future research directions for 5-Bromo-2-(difluoromethyl)benzoic acid appear promising. Several ongoing studies are exploring its incorporation into PROTAC molecules and other targeted protein degradation platforms. Additionally, computational chemistry approaches are being employed to better predict its behavior in various biological systems, potentially accelerating its adoption in drug discovery pipelines.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)